Home Newsfeeds Needham Reiterates Buy on HashiCorp, Maintains $39 Price Target

Needham Reiterates Buy on HashiCorp, Maintains $39 Price Target

Needham analyst Alex Henderson reiterates HashiCorp (NASDAQ:HCP) with a Buy and maintains $39 price target.

byBenzinga Newsdesk

March 10, 2023

1 minute read

Needham analyst Alex Henderson reiterates HashiCorp (NASDAQ:HCP) with a Buy and maintains $39 price target.

Recap: Granite Construction Q2 Earnings

By Benzinga Insights

July 28, 7:18 AM

Granite Construction (NYSE:GVA) reported its Q2 earnings results on Thursday, July 28, 2022 at 06:45 AM. Here's what investors need to know about the announcement.

GVA

Arconic Clocks 21% Sales Growth In Q3 Aided By Its Segments; Slashes FY22 Outlook

By Anusuya Lahiri

November 1, 10:52 AM

Arconic Corp (NYSE:ARNC) reported third-quarter sales growth of 21% year-over-year to $2.3 billion, beating the consensus of $2.17 billion. Net…

ARNC

2008 ‘Big Short’ Oracle Burry Bets Big On Chinese Giants, Backs Google, Amazon’s AI Wave

By Piero Cingari

February 14, 5:09 PM

Michael Burry, the visionary investor, made significant changes to his portfolio in Q4 2023. Increased stakes in Chinese retailers and two US tech giants, divested from four companies and reduced holdings in others.

AMZN

Ironwood Pharmaceuticals Lowers 2024 Guidance: Now Expects Sales Between $405M-$425M (Prior $435M-$455M) Vs. 447.9M Consensus; Sees Adjusted EBITDA Above $120M

By Benzinga Newsdesk

May 9, 7:31 AM

Ironwood 2024 Financial Guidance. Ironwood has revised its FY 2024 financial guidance due to a LINZESS gross-to-net change in estimate related to the year ended December 31, 2023. Ironwood now

IRWD

Needham Reiterates Buy on HashiCorp, Maintains $39 Price Target

Related Posts

Recap: Granite Construction Q2 Earnings

Arconic Clocks 21% Sales Growth In Q3 Aided By Its Segments; Slashes FY22 Outlook

2008 ‘Big Short’ Oracle Burry Bets Big On Chinese Giants, Backs Google, Amazon’s AI Wave

Ironwood Pharmaceuticals Lowers 2024 Guidance: Now Expects Sales Between $405M-$425M (Prior $435M-$455M) Vs. 447.9M Consensus; Sees Adjusted EBITDA Above $120M